From Lab to Living Room: The Four Principles Behind Healthtech Devices People Actually Use

A healthtech device can pass every lab test, hit every performance benchmark, and still fail in the market. Not because the underlying technology was wrong but because of what happened in the space between the lab bench and the person actually using it at home, under real conditions, without a technician standing by.

Across the medtech and healthtech device work we do; this is the pattern that shows up again and again. The products that succeed and the products that struggle are rarely separated by the quality of the core science. They're separated by four design disciplines that rarely get the attention they deserve.

1. Ergonomics: designing for the actual user, not the average user

It's tempting to validate ergonomics against a convenient test population: healthy adults, steady hands, good dexterity. But in healthcare specifically, the person who most needs a device is often the person least represented in that convenient test group: older patients, patients with reduced grip strength or tremors, patients managing the very condition the device is meant to help with.

A device designed around an idealized user isn't really designed for its real user at all. Ergonomic testing that only reflects easy cases is testing the wrong population and the gap between "worked in testing" and "works for the people who need it" is exactly where healthtech products lose trust.

2. Usability: designing for the real environment, not the demo

A device that performs flawlessly under lab lighting, on a clean bench, with a trained operator nearby, tells you very little about whether it will perform correctly at home, half-asleep, under stress, on the first try, with nobody to ask for help.

Real-world usability testing, in the actual conditions the device will be used in, by the actual people who'll use it, surfaces failure modes that lab testing simply can't. This is expensive and slow compared to bench testing, which is exactly why it's the step most often compressed or skipped under deadline pressure. It's also, consistently, the step whose absence shows up loudest in return rates and complaint volume after launch.

3. Manufacturability: designing to survive the jump from prototype to production

A working prototype is built under conditions no production line can replicate at scale: hand-finishing, premium materials, unlimited time per unit. The real design discipline is figuring out what has to change to hit a production cost and volume target without quietly losing the properties that made the prototype work in the first place.

This is where a lot of erosion happens, one small decision at a time. A tolerance gets loosened slightly to ease manufacturing. A component gets swapped for a cheaper, functionally "equivalent" one. Individually, each change looks negligible. Collectively, they can turn a device that performed well in testing into one that underperforms in the field, without anyone deciding, at any single point, to compromise the product.

4. Validation on the population that will actually use it

This is the quietest of the four principles, and arguably the most consequential. A device can pass every lab benchmark and still underperform in the real world if the validation study behind it didn't represent the people who will actually rely on it.

The clearest illustration of this in recent medtech history is the pulse oximeter, the clip-on finger sensor that became a household device during the COVID-19 pandemic. The underlying technology is sound: it estimates blood oxygen by shining light through the fingertip and measuring absorption. But melanin absorbs light too, and the devices in wide use were validated on study populations that skewed toward lighter skin tones.

A landmark study published in the New England Journal of Medicine in December 2020 found that Black patients had close to three times the rate of occult hypoxemia, dangerously low blood oxygen that the pulse oximeter failed to detect, compared to white patients, because the devices were producing falsely normal readings (Sjoding et al., NEJM, 2020; DOI: 10.1056/NEJMc2029240). The finding was significant enough that the FDA issued a formal safety communication in 2021 and has since released draft guidance requiring manufacturers to validate devices against a genuinely representative range of skin tones: testing on at least 150 participants, with meaningful representation across light, medium, and dark skin.

Notably, a follow-up FDA-commissioned study released in early 2026 produced more mixed and inconclusive results than expected and has not yet completed peer review, a reminder that validating for a representative population isn't a one-time fix. It's an ongoing design discipline, not a checkbox that gets closed once and forgotten.

What good validation looks like, by contrast

Continuous glucose monitors, the small adhesive sensors worn on the upper arm for continuous blood sugar tracking, are a useful counterexample. Their success wasn't just about the underlying sensor technology, which existed in various forms before these devices reached mass adoption. It was about the ergonomic and usability decisions layered on top: an applicator simple enough for a shaking or unsteady hand to use correctly on the first attempt, an adhesive engineered to survive showering, sweating, and sleeping without failing, and a design that eliminated the single biggest adherence barrier in diabetes management, the repeated finger-prick.

Every one of those was a deliberate design decision made for the user's actual daily life, not for a lab-testing environment. That's the difference this article is really about.

Building this into your process, not bolting it on at the end

The founders and product teams who get this right build ergonomics, real-world usability, manufacturability, and representative validation into the process from early prototyping, not as a final round of testing before launch. Retrofitting these disciplines after a design is largely locked is far more expensive, both in redesign cost and, more importantly, in the trust a product loses if it reaches real users before these gaps are closed.

None of these four principles are exciting. They rarely make it into a pitch deck. But they are, consistently, the actual difference between a healthtech device that gets adopted and trusted, and one that gets returned, misused, or quietly abandoned.

Hexaura works across medtech and healthtech device development, from early ergonomic and usability research through manufacturability and production. If your validation process hasn't been stress-tested against your hardest, most different user, that's usually exactly where the risk is hiding and it's worth finding before launch, not after.